Molecularly Targeted Radiosensitization of Human Prostate Cancer by Modulating Inhibitor of Apoptosis
- 1 December 2008
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 14 (23) , 7701-7710
Abstract
Purpose: The inhibitor of apoptosis proteins (IAP) are overexpressed in hormone-refractory prostate cancer, rendering the cancer cells resistant to radiation. This study aims to investigate the radiosensitizing effect of small-molecule IAP inhibitor both in vitro and in vivo in androgen-independent prostate cancer and the possible mechanism of radiosensitization. Experimental Design: Radiosensitization of SH-130 in human prostate cancer DU-145 cells was determined by clonogenic survival assay. Combination effect of SH-130 and ionizing radiation was evaluated by apoptosis assays. Pull-down and immunoprecipitation assays were employed to investigate the interaction between SH-130 and IAPs. DU-145 xenografts in nude mice were treated with SH-130, radiation, or combination, and tumor suppression effect was determined by caliper measurement or bioluminescence imaging. Nuclear factor-κB activation was detected by luciferase reporter assay and quantitative real-time PCR. Results: SH-130 potently enhanced radiation-induced caspase activation and apoptosis in DU-145 cells. Both X-linked IAP and cIAP-1 can be pulled down by SH-130 but not by inactive SH-123. Moreover, SH-130 interrupted interaction between X-linked IAP/cIAP-1 and Smac. In a nude mouse xenograft model, SH-130 potently sensitized the DU-145 tumors to X-ray radiation without increasing systemic toxicity. The combination therapy suppressed tumor growth more significantly than either treatment alone, with over 80% of complete tumor regression. Furthermore, SH-130 partially blocked tumor necrosis factor-α- and radiation-induced nuclear factor-κB activation in DU-145 cells. Conclusions: Our results show that small-molecule inhibitors of IAPs can overcome apoptosis resistance and radiosensitize human prostate cancer with high levels of IAPs. Molecular modulation of IAPs may improve the outcome of prostate cancer radiotherapy.Keywords
All Related Versions
This publication has 41 references indexed in Scilit:
- Autocrine TNFα Signaling Renders Human Cancer Cells Susceptible to Smac-Mimetic-Induced ApoptosisCancer Cell, 2007
- Palliative radiation therapy for localized prostate symptoms in hormone refractory prostate cancerAustralasian Radiology, 2007
- XIAP Induces NF-κB Activation via the BIR1/TAB1 Interaction and BIR1 DimerizationMolecular Cell, 2007
- Embelin, an Inhibitor of X Chromosome-Linked Inhibitor-of-Apoptosis Protein, Blocks Nuclear Factor-κB (NF-κB) Signaling Pathway Leading to Suppression of NF-κB-Regulated Antiapoptotic and Metastatic Gene ProductsMolecular Pharmacology, 2007
- NF-κB modulation and ionizing radiation: mechanisms and future directions for cancer treatmentCancer Letters, 2006
- IAPs are functionally non-equivalent and regulate effector caspases through distinct mechanismsNature Cell Biology, 2004
- A Small Molecule Smac Mimic Potentiates TRAIL- and TNFα-Mediated Cell DeathScience, 2004
- In Vivo Visualization of Metastatic Prostate Cancer and Quantitation of Disease Progression in Immunocompromised MiceCancer Biology & Therapy, 2003
- IAP proteins: blocking the road to death's doorNature Reviews Molecular Cell Biology, 2002
- NF-κB signaling pathway as a target for human tumor radiosensitizationSeminars in Radiation Oncology, 2001